Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...

so the new data – if added to Libtayo's label – could allow the drug to directly challenge the class leader. Sanofi and Regeneron say they now plan to filed for approvals in the US and Europe ...

In 2025, approvals are expected in Europe and Japan ... Key products like EYLEA, Libtayo, and Dupixent propelled the company’s growth. Dupixent continues to be a major success, treating over ...

The European Film Academy recorded nearly half a million admissions for its November 2024 screenings, part of a broader plan to create an Oscar-style "awards season" for European cinema.

Photo: Francis Chung/Press Pool But if the European Union imposes a 50% retaliatory tariff on the company’s motorcycles in April, prices could reach astounding heights in Harley’s second ...

Now, Europe is playing catch-up. Since the end of World War II, Europe has been guaranteed US security. And for the 31 other member states under the NATO alliance, that meant the US would spring ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...

DUBLIN, April 2 (Reuters) - Ryanair (RYA.I), opens new tab flew 200.2 million passengers in its fiscal year to the end of March, largely as forecast, making it the first European airline to carry ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands ...

Philogen SpA reported a significant increase in its full-year 2024 revenues, reaching €77.5 million, a threefold rise compared to the previous year. Despite the impressive financial performance ...